Between the trial and the treatment.

The last issue laid out why intismeran autogene and the platform behind it look like the arrival of personalized medicine in cancer care. Here’s what it actually means to access something like it today, not in five years.

Intismeran itself is not commercially available. Approval submissions for the melanoma indication are expected in the next 12 to 18 months. Everything below the intismeran line is the wider category of personalized neoantigen immunotherapies, which spans a spectrum from Phase 3 trials in academic centers to private clinics of variable quality. The four pathways below cover it, in ascending order of skepticism required.

1. Clinical trial enrollment. The cleanest path. Nine INTerpath trials are recruiting across melanoma, non-small cell lung, bladder, and renal cancers. Enrollment goes through oncologists at academic medical centers, which check trial eligibility against tumor type, stage, prior treatment history, and other criteria. There is no charge to the patient for the experimental drug itself. The waitlist and geographic reality do rule out many people who would otherwise qualify. ClinicalTrials.gov is the searchable database that ties this together, and a treating oncologist is the person to enroll through.

2. FDA-authorized Expanded Access Programs. The second-cleanest path. The FDA runs cost-recovery expanded access programs that let patients receive experimental treatments outside of trials, under specific eligibility criteria. The most relevant one for personalized neoantigen vaccines is run by the Jaime Leandro Foundation, which offers personalized neoantigen peptide vaccines through the FDA framework. Reported cost for a full vaccine series is around $92,000. Eligibility is limited to patients without curative therapies and with a projected 5-year survival below 50 percent, so it is not open to everyone with cancer. Timeline from sequencing to first dose is roughly four to five months.

3. Right-to-Try law pathways. The federal Right to Try Act (2018) allows terminally ill patients to access investigational drugs that have completed Phase 1 but are not yet FDA-approved. In 2023, Montana passed SB 422, the first US law to remove the terminal-illness restriction and open Right-to-Try to any patient who has considered all approved options and gives informed consent. That framework has opened Montana clinics to offer a wider range of personalized immunotherapies to non-terminal patients, at prices that generally run in the $50,000 to $150,000 range depending on the specific protocol. Not the intismeran product. And the evidence base varies materially by provider.

4. Private clinics outside the frameworks above. Ranging from established international clinics (Germany, Mexico, the Bahamas) to smaller US-based operations, this pathway offers a broad range of what gets marketed as “personalized cancer immunotherapy.” The category includes dendritic cell vaccines, autologous cell therapies, and various neoantigen-based protocols. Some of these have real evidence behind them. Many do not. Pricing spans $30,000 to $500,000 plus depending on the clinic and the treatment. The distinction between “expensive but genuinely experimental” and “expensive but not much more than hope” is what a treating oncologist and an independent second opinion should be helping to sort. Never a Google search alone.

For most people asking about personalized cancer immunotherapy today, the honest sequence is: talk to a treating oncologist first, search ClinicalTrials.gov for open enrollment second, evaluate the FDA-authorized expanded access programs third, and only consider the state Right-to-Try pathways or private clinics fourth. The order matters because the evidence quality drops sharply as you move down the list, and the price tag climbs.

The larger point remains the one from the last issue. The science that made intismeran work is real. The pricing that big pharma is signaling for it is not the pricing that a personalized mRNA vaccine actually costs to produce at scale. If breakthroughs of this magnitude are going to change cancer outcomes for anyone beyond the wealthiest slice of the population, the industry has to bend the price curve down as the platform scales.

The next issue takes the three moves worth making this week to reduce your cancer risk while personalized medicine matures. The screening you may not be current on. The lifestyle levers with the strongest evidence. And the one audit most people never do.

Longevity Daily / The Building Decades